ARIDOL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ARIDOL (ARIDOL).
Aridol (mannitol) is an osmotic agent that, when inhaled, increases airway osmolarity, leading to release of mediators from mast cells and eosinophils, causing bronchoconstriction in susceptible individuals. It is used as a bronchial challenge test to assess airway hyperresponsiveness.
| Metabolism | Mannitol is not metabolized; it is excreted unchanged by the kidneys. |
| Excretion | Primarily renal excretion of unchanged mannitol. Approximately 80% of the administered dose is excreted unchanged in urine within 12 hours; minor biliary/fecal elimination (<5%). |
| Half-life | 16.1 ± 8.5 minutes in healthy adults. Clinical context: Short half-life allows repeated provocative testing within 2–3 hours. |
| Protein binding | Essentially 0% (mannitol is not protein bound). |
| Volume of Distribution | 0.28 L/kg (approximately 20 L in 70 kg adult). Clinical meaning: Distribution limited to extracellular fluid; mannitol remains extracellular. |
| Bioavailability | Inhalation: Systemic bioavailability is approximately 10–20% of the inhaled dose (due to local airway deposition and limited absorption). Oral: Not applicable. |
| Onset of Action | Inhalation: Decline in FEV1 ≥20% typically occurs within 5–15 minutes post-inhalation. |
| Duration of Action | Bronchoconstriction resolves spontaneously within 30–60 minutes. FEV1 returns to baseline by 60 minutes, enabling repeat testing same day. |
For bronchial challenge testing: inhaled dose of 5 mg (one vial) via nebulizer, single administration.
| Dosage form | POWDER |
| Renal impairment | No dose adjustment required; ARIDOL is renally excreted but systemic absorption minimal. |
| Liver impairment | No dose adjustment required; not metabolized by liver. |
| Pediatric use | For bronchial challenge testing in children ≥6 years: 5 mg inhaled via nebulizer, same as adult dose. |
| Geriatric use | Use standard adult dose; no specific adjustment, but monitor for bronchospasm due to potential comorbidities. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ARIDOL (ARIDOL).
| Breastfeeding | Excretion into human milk unknown. Mannitol is a small molecule (MW 182) potentially excreted. M/P ratio not established. Breastfeeding not recommended during procedure; consider pumping and discarding milk for 24 hours post-administration. Caution in neonates due to immature renal function. |
| Teratogenic Risk | Aridol (mannitol) is a diagnostic osmotic agent. No adequate studies in pregnant women. Animal studies not available. Teratogenic risk cannot be excluded. Use only if clearly needed. First trimester: theoretical risk of fetal osmotic disturbances. Second/third trimesters: potential for fetal dehydration or electrolyte imbalance if maternal hyperosmolality occurs. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to mannitol or any component of the formulation","Severe asthma (FEV1 < 50% predicted or < 1.0 L)","History of life-threatening asthma or status asthmaticus","Recent asthma exacerbation requiring hospitalization or oral corticosteroid therapy within the prior 2 weeks","Acute respiratory tract infection with bronchospasm"]
| Precautions | ["Should only be administered by trained healthcare professionals in a setting equipped to manage acute bronchospasm","Not for use in patients with known hypersensitivity to mannitol","Contraindicated in patients with severe asthma (FEV1 < 50% predicted or < 1.0 L), or conditions that could be exacerbated by bronchoconstriction","Monitor FEV1 after each dose; test should be stopped if FEV1 drops by ≥ 15% from baseline or symptoms develop","Have short-acting beta-agonist available for immediate treatment of bronchospasm","Use caution in patients with unstable asthma or respiratory infection"] |
| Food/Dietary | Avoid caffeine-containing foods and beverages (coffee, tea, cola, chocolate) for 8 hours before the test, as they may affect bronchial reactivity. No other dietary restrictions. |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum electrolytes, osmolality, and renal function before and after administration. During bronchial challenge test, monitor for bronchospasm, oxygen saturation, and signs of hypersensitivity. Fetal heart rate monitoring if gestational age >24 weeks during prolonged procedures. Observe for maternal hypotension or syncope. |
| Fertility Effects | No human data on fertility. In animal studies, no adverse effects on fertility reported. Transient osmotic effects could theoretically impact hormonal balance or implantation, but not clinically significant with single diagnostic use. |
| Clinical Pearls | ARIDOL (mannitol dry powder inhalation) is a bronchial provocation test for diagnosing asthma. Use FEV1 as the primary endpoint; a drop of ≥15% from baseline indicates a positive test. Avoid in patients with FEV1 < 1.5 L or < 60% predicted. Administer via specific inhaler device; ensure capsule piercing and proper inhalation technique. Monitor for bronchospasm; have rescue bronchodilator available. |
| Patient Advice | This test measures airway sensitivity to mannitol. · Avoid caffeine, smoking, and short-acting bronchodilators for 8 hours before the test. · Do not use this test if you have a current respiratory infection or severe asthma. · You may experience coughing or throat irritation during the test. · Follow the breathing instructions carefully; inhale forcefully and deeply after each capsule is pierced. |